Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline [Seeking Alpha]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Seeking Alpha
Revenue visibility anchors downside risk; the investment thesis pivots to execution—specifically, controlling SG&A growth relative to incremental pipeline-driven revenue. Pipeline opportunities in Alzheimer's agitation and narcolepsy could conservatively add $375M+ in annual revenue, but value creation hinges on SG&A discipline. AXSM is a narrow but defensible buy, contingent on SG&A growth staying below 40% of incremental revenue to unlock operating leverage. Richard Drury/DigitalVision via Getty Images Introduction: Axsome's Investment Question Has Changed Axsome Therapeutics ( AXSM ) develops CNS drugs and has three marketed products. These are Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, and This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the nex
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Leerink Partners from $150.00 to $205.00. They now have an "outperform" rating on the stock.MarketBeat
- Top Picks 2026- Dynex Capital Inc. DX [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23GlobeNewswire
- How The New Price Target Is Shaping The Axsome Therapeutics (AXSM) Investment Story [Yahoo! Finance]Yahoo! Finance
AXSM
Earnings
- 11/3/25 - Miss
AXSM
Sec Filings
- 1/23/26 - Form 4
- 1/23/26 - Form 4
- 1/22/26 - Form 144
- AXSM's page on the SEC website